KR100669836B1 - 신규한 아릴옥시-알킬-디알킬아민 및 이의 제조 방법 - Google Patents

신규한 아릴옥시-알킬-디알킬아민 및 이의 제조 방법 Download PDF

Info

Publication number
KR100669836B1
KR100669836B1 KR1020007004031A KR20007004031A KR100669836B1 KR 100669836 B1 KR100669836 B1 KR 100669836B1 KR 1020007004031 A KR1020007004031 A KR 1020007004031A KR 20007004031 A KR20007004031 A KR 20007004031A KR 100669836 B1 KR100669836 B1 KR 100669836B1
Authority
KR
South Korea
Prior art keywords
alkyl
group
substituted
formula
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020007004031A
Other languages
English (en)
Korean (ko)
Other versions
KR20010024505A (ko
Inventor
래빈드래내쓰파놀릴
젤디스조셉
비드갤리나
포토스키존리차드
렌장진
Original Assignee
와이어쓰
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/161,653 external-priority patent/US6005102A/en
Application filed by 와이어쓰 filed Critical 와이어쓰
Publication of KR20010024505A publication Critical patent/KR20010024505A/ko
Application granted granted Critical
Publication of KR100669836B1 publication Critical patent/KR100669836B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Detergent Compositions (AREA)
  • Indole Compounds (AREA)
KR1020007004031A 1997-10-15 1998-10-14 신규한 아릴옥시-알킬-디알킬아민 및 이의 제조 방법 Expired - Fee Related KR100669836B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US95081897A 1997-10-15 1997-10-15
US08/950,818 1997-10-15
US09/161,653 US6005102A (en) 1997-10-15 1998-09-28 Aryloxy-alkyl-dialkylamines
US09/161,653 1998-09-28
PCT/US1998/021609 WO1999019293A1 (en) 1997-10-15 1998-10-14 Novel aryloxy-alkyl-dialkylamines

Publications (2)

Publication Number Publication Date
KR20010024505A KR20010024505A (ko) 2001-03-26
KR100669836B1 true KR100669836B1 (ko) 2007-01-18

Family

ID=26858006

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020007004031A Expired - Fee Related KR100669836B1 (ko) 1997-10-15 1998-10-14 신규한 아릴옥시-알킬-디알킬아민 및 이의 제조 방법

Country Status (26)

Country Link
EP (2) EP1777214A3 (https=)
JP (1) JP2001519410A (https=)
KR (1) KR100669836B1 (https=)
CN (1) CN1231458C (https=)
AR (1) AR015183A1 (https=)
AT (1) ATE355264T1 (https=)
AU (1) AU757630C (https=)
BR (1) BR9813069A (https=)
CA (1) CA2306343C (https=)
CY (1) CY1106497T1 (https=)
DE (1) DE69837210T2 (https=)
DK (1) DK1025077T3 (https=)
EA (1) EA003937B1 (https=)
EE (1) EE200000225A (https=)
ES (1) ES2281937T3 (https=)
HU (1) HUP0004419A3 (https=)
ID (1) ID24417A (https=)
IL (2) IL135343A0 (https=)
NO (1) NO20001938L (https=)
NZ (1) NZ503793A (https=)
PL (1) PL198443B1 (https=)
PT (1) PT1025077E (https=)
SI (1) SI1025077T1 (https=)
SK (1) SK286460B6 (https=)
TR (1) TR200001012T2 (https=)
WO (1) WO1999019293A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA005932B1 (ru) * 1998-05-15 2005-08-25 Уайт 2-фенил-1-[4-(2-аминоэтокси)бензил]индол в комбинации с эстрогенами
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
CA2382683A1 (en) * 1999-09-13 2001-03-22 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-¬4-(2-amin-1-yl-ethoxy)-benzyl|-1h-indol-5-ols
US6455568B2 (en) 2000-07-06 2002-09-24 Wyeth Combination therapy for inhibiting sphincter incontinence
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
AU2001273144A1 (en) 2000-07-06 2002-01-21 Wyeth Use of substituted indole compounds for treating neuropeptide y-related conditions
MXPA03000170A (es) 2000-07-06 2003-05-27 Wyeth Corp Combinaciones de un inhibidor de recaptacion de serotonina selectivo y agentes estrogenicos.
AR029539A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Combinaciones de estatinas y agentes estrogenicos
EP1656938A1 (en) 2000-07-06 2006-05-17 Wyeth Combinations of SSRI and estrogenic agents
WO2002003990A2 (en) 2000-07-06 2002-01-17 Wyeth Use of substituted insole compounds for treating excessive intraocular pressure
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
US6369051B1 (en) 2000-07-06 2002-04-09 American Home Products Corporation Combinations of SSRI and estrogenic agents
JP2004532834A (ja) * 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
JP2004531559A (ja) 2001-05-22 2004-10-14 イーライ・リリー・アンド・カンパニー エストロゲン欠乏または内因性エストロゲンに対する異常な生理反応に関連する疾患を抑制するためのテトラヒドロキノリン誘導体
EP1395563B1 (en) 2001-05-22 2006-03-29 Eli Lilly And Company 2-substituted 1,2,3,4-tetrahydroquinolines and derivatives thereof, compositions and methods
US7314937B2 (en) 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
US7098241B2 (en) 2002-12-16 2006-08-29 Hoffmann-La Roche Inc. Thiophene hydroxamic acid derivatives
WO2005100316A1 (en) 2004-04-07 2005-10-27 Wyeth Crystalline polymorph of a bazedoxifene acetate
JP2007532548A (ja) 2004-04-07 2007-11-15 ワイス バゼドキシフェンアセテートの結晶質多形体
MXPA06011686A (es) 2004-04-08 2006-12-14 Wyeth Corp Ascorbato de bazedoxifeno como modulador del receptor de estrogeno selectivo.
JP2008509148A (ja) * 2004-08-05 2008-03-27 ワイス 塩酸ピピンドキシフェン一水和物の結晶多形
EP1836155A2 (en) * 2005-01-13 2007-09-26 Wyeth, A Corporation of the State of Delaware Processes for the preparation of aminoethoxybenzyl alcohols
US20100087661A1 (en) * 2007-02-12 2010-04-08 Josef Jirman Method for the preparation of 5-benzyloxy-2-(4-benzyloxphenyl)-3-methyl-1h-indole
WO2009102771A1 (en) * 2008-02-11 2009-08-20 Wyeth Methods of converting polymorphic form b of bazedoxifene acetate to polymorphic form a of bazedoxifene acetate
CA2758109A1 (en) * 2009-04-13 2010-10-21 Sandoz Ag Processes for the synthesis of bazedoxifene acetate and intermediates thereof
US8569483B2 (en) 2011-06-21 2013-10-29 Divi's Laboratories, Ltd. Process for the preparation of bazedoxifene acetate and intermediates thereof
CN104151265B (zh) * 2013-05-13 2016-10-05 上海医药工业研究院 醋酸巴多昔芬中间体的制备方法
US9751835B2 (en) 2013-05-15 2017-09-05 Indiana University Research And Technology Corporation Processes and intermediates for preparing indole pharmaceuticals
IT201800006562A1 (it) * 2018-06-21 2019-12-21 Procedimento e intermedi utili per la preparazione di indoli
IT201900001923A1 (it) 2019-02-11 2020-08-11 Erregierre Spa Sali di bazedoxifene utili per la preparazione di bazedoxifene acetato

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428312A2 (en) * 1989-11-13 1991-05-22 Pfizer Inc. Oxazolidinedione hypoglycemic agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH448121A (de) 1963-03-13 1967-12-15 Hoffmann La Roche Verfahren zur Herstellung substituierter Hydrazinverbindungen
GB9326332D0 (en) 1993-12-23 1994-02-23 Karo Bio Indole derivatives
CA2259487A1 (en) * 1996-07-01 1998-01-08 Margaret Mary Faul Hypoglycemic and hypolipidemic compounds
YU40999A (sh) * 1997-02-27 2002-06-19 American Cyanamid Company N-hidroksi-2-(alkil,aril ili heteroaril sulfanil,sulfinil ili sulfonil)-3-supstituisani alkil,aril ili heteroarilamidi, kao inhibitori za matrične metaloproteinaze
EP1011666A4 (en) * 1997-04-30 2004-03-31 Lilly Co Eli ANTITHROMBOTIC AGENTS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0428312A2 (en) * 1989-11-13 1991-05-22 Pfizer Inc. Oxazolidinedione hypoglycemic agents

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J. of Chem. Soc., 1965 *

Also Published As

Publication number Publication date
WO1999019293A1 (en) 1999-04-22
AR015183A1 (es) 2001-04-18
EP1025077B1 (en) 2007-02-28
PT1025077E (pt) 2007-05-31
CA2306343A1 (en) 1999-04-22
AU757630B2 (en) 2003-02-27
EP1025077A1 (en) 2000-08-09
NZ503793A (en) 2002-10-25
HUP0004419A2 (hu) 2001-07-30
DE69837210T2 (de) 2007-12-27
CN1281429A (zh) 2001-01-24
SK5372000A3 (en) 2000-11-07
IL135343A (en) 2007-12-03
ATE355264T1 (de) 2006-03-15
CN1231458C (zh) 2005-12-14
EA003937B1 (ru) 2003-10-30
AU757630C (en) 2006-10-26
SI1025077T1 (sl) 2007-06-30
PL339908A1 (en) 2001-01-15
JP2001519410A (ja) 2001-10-23
AU1083199A (en) 1999-05-03
TR200001012T2 (tr) 2000-09-21
CA2306343C (en) 2010-08-03
PL198443B1 (pl) 2008-06-30
DK1025077T3 (da) 2007-05-07
SK286460B6 (sk) 2008-10-07
EP1777214A3 (en) 2007-05-09
ID24417A (id) 2000-07-20
EE200000225A (et) 2001-06-15
ES2281937T3 (es) 2007-10-01
HUP0004419A3 (en) 2002-01-28
IL135343A0 (en) 2001-05-20
NO20001938D0 (no) 2000-04-13
HK1026889A1 (en) 2000-12-29
NO20001938L (no) 2000-06-07
CY1106497T1 (el) 2012-01-25
EA200000416A1 (ru) 2000-10-30
EP1777214A2 (en) 2007-04-25
KR20010024505A (ko) 2001-03-26
BR9813069A (pt) 2000-08-22
DE69837210D1 (de) 2007-04-12

Similar Documents

Publication Publication Date Title
KR100669836B1 (ko) 신규한 아릴옥시-알킬-디알킬아민 및 이의 제조 방법
US6242605B1 (en) Aryloxy-alkyl-dialkylamines
JP5607871B2 (ja) エストロゲンと組み合わせる２−フェニル−１−［４−（２−アミノエトキシ）ベンジルオキシ］インドール
US7247624B2 (en) 2-Phenyl-1-[4-(2-aminoethoxy)-benzyl]-indoles as estrogenic agents
HU227077B1 (en) Estrogenical 2-phenyl-1-benzyl-indole derivatives, preparation and use thereof and pharmaceutical compositions containing these compounds
US5985910A (en) 3- [4- (2- Phenyl-Indole-1-ylmethyl) Phenyl]- Acrylamides as estrogenic agents
EP0835868B1 (en) 2-Aryl-3-aminoaryloxynaphthyl compounds, intermediates, compositions and methods
US5929090A (en) 2-aryl-3-aminoaryloxynaphthy1 compounds, intermediates, compositions and methods
CZ20001368A3 (cs) Aryloxyalkyldialkylaminy
MXPA00003694A (en) Novel aryloxy-alkyl-dialkylamines
HK1096954A (en) Novel aryloxy-alkyl-dialkylamines
HK1026889B (en) Novel aryloxy-alkyl-dialkylamines
UA73916C2 (en) Novel aryloxyalkyldialkylamines
MXPA00011178A (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens
CA2558821A1 (en) 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]indoles as estrogenic agents

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20091230

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20110111

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20110111

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000